{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.48","value":"8.7"},{"groupId":"OG001","spread":"1.26","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Tumor response was assessed as PR based on IMWG response criteria as \\>=50% reduction of serum and reduction in 24-h urinary M protein by \\>=90% or to \\<200 mg/24 h; or serum/urine M protein unmeasurable:\\>=50% decrease in the difference between involved and uninvolved FLC levels; or serum/urine M protein and FLC assay unmeasurable: \\>=50% reduction in plasma cells provided baseline bone marrow plasma cell percentage was \\>=30%; or plus if present at baseline: \\>=50% reduction in size of soft tissue plasmocytomas.","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"NUMBER","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Tumor Response: Percentage of Participants With Partial Response (PR) Based on International Myeloma Working Group (IMWG) Response Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}